A new drug (apalutamide) has been approved in the US for the treatment of metastatic PC. It is now being submitted to regulators in Canada for approval for metastatic castrate-sensitive prostate cancer (mCSPC). Canada Cancer Survivor Network is leading the patient submission process in order to share patient experiences and opinions with the review committee. They have developed a patient survey which will be open until October 23rd. We invite you to participate:
Here are the details:
Opportunity to share your prostate cancer journey—The purpose of the survey is to provide the Canadian Cancer Survivor Network (CCSN) with insights and perspectives about living with and managing prostate cancer from patients and caregivers in order to complete a patient evidence submission for apalutamide, a new medication for metastatic castrate-sensitive prostate cancer (mCSPC) that is seeking approval for use by patients in Canada.
The survey will remain open until October 23, 2019. –The pan-Canadian Oncology Drug Review invites patient groups to prepare and send in submissions so that patients and caregivers like you can be heard. Please join us and have your voice included in this important submission process.
If you do not have metastatic castrate-sensitive prostate cancer (mCSPC), but believe that you would benefit from this treatment, please complete the survey. survey
Thank you for your participation.
Please also note that this survey is administered by an external provider. Prostate Cancer Canada does not approve, endorse or recommend any specific product or service but provides information to assist individuals in making their own decisions. Prostate Cancer Canada assumes no responsibility for any personal or contact information provided to the service provider when you participate in the survey.
Many thanks and Happy Thanksgiving to all,
Anne Breakey Hart, CVA
Manager, PCCN and Volunteer Engagement | Prostate Cancer Canada
Gestionnaire, Mobilisation des bénévoles | Cancer de la Prostate Canada
T 416-441-2131 ext./poste 229 | E firstname.lastname@example.org